posted on 2021-07-07, 17:33authored byYinqiu Wang, Aolei Niu, Yu Pan, Shirong Cao, Andrew S.Terker, Suwan Wang, Xiaofeng Fan, Cynthia L Toth, Marisol A Ramirez Solano, Danielle L Michell, Danielle Contreras, Ryan M Allen, Wanying Zhu, Quanhu Sheng, Agnes B. Fogo, Kasey C Vickers, Ming-Zhi Zhang, Raymond C. Harris
Podocyte injury is important in development of diabetic nephropathy (DN). Although several
studies have reported single
cell-based RNA-seq of podocytes in type 1 DN (T1DN), the podocyte translating mRNA profile in type 2 DN
(T2DN) <u>has not been previously compared</u> to
that of T1DN. <u>We</u> analyzed the podocyte translatome in T2DN in podocin-Cre; Rosa26<sup>fsTRAP</sup>;
eNOS-/-; <i>db/db </i>mice and compared it to streptozotocin-induced T1DN in podocin-Cre; Rosa26<sup>fsTRAP</sup>; eNOS-/-
mice utilizing Translating
Ribosome Affinity Purification (TRAP) and RNA-seq. Over 125 genes were highly enriched in the podocyte
ribosome. More podocyte
TRAP genes were differentially expressed in T2DN compared to T1DN. TGF-β
signaling pathway genes were upregulated while
MAPK pathway genes were downregulated only in T2DN while ATP binding and
cAMP-mediated signaling genes were
downregulated only in T1DN. Genes regulating actin filament organization and apoptosis increased while genes
regulating VEGFR signaling and glomerular
basement membrane components
decreased in both type 1 and type 2 diabetic podocytes. A number diabetes-induced genes not previously been
linked to podocyte injury <u>were confirmed in both</u> <u>mouse and human DN</u>. Differences and similarities in the podocyte
translatome in T2DN and T1DN can identify factors underlying the
pathophysiology of DN and novel therapeutic targets to treat diabetes-induced podocyte injury.
Funding
These studies were supported by National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIH grants DK51265, DK95785, and DK62794 (to R.C.H. and M.-Z.Z.); NIDDK grant DK103067 (to R.C.H., A.B.F., K.C.V. and M.-Z.Z.) and the Vanderbilt O’Brien Center (NIDDK grant P30DK114809) (to R.C.H. and M.-Z.Z.); U.S. Department of Veterans Affairs VA Merit Award 00507969 (R.C.H.); the Vanderbilt Center for Kidney Disease.